Kids taking Xeljanz for juvenile arthritis study
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study is collecting real-world information about how Xeljanz (tofacitinib) is used and how well it works in children with juvenile idiopathic arthritis. It may help improve how the medicine is used safely in everyday care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 2 and under 18 years old
- Be taking Xeljanz for juvenile idiopathic arthritis as instructed on the approved label
- A doctor must decide that Xeljanz is appropriate for your child’s care
- You (and your child, if applicable) must sign and date a consent form after being told about the study
- Your child must not have a medical reason they are not allowed to take Xeljanz based on the approved label
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects real-world safety information about Xeljanz XR after it has been approved. It includes people with certain immune-related joint diseases and checks for side effects in everyday use.
This trial tests the drug tofacitinib in children with juvenile idiopathic arthritis (a type of arthritis that starts before age 18). It looks at whether tofacitinib is a safe and effective treatment for this condition.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This trial tests a new medicine called olokizumab in children and teenagers with juvenile idiopathic arthritis (JIA)—a condition where the immune system causes joint inflammation and pain. The study checks if this drug is safe and effective for children whose arthritis hasn't improved enough with standard treatments.
This study tests two drugs—risankizumab and adalimumab—to see which is safer and works better for children with active psoriatic arthritis. It's for kids who have not been helped enough by standard disease-modifying drugs.
This Phase 3 study tests whether children with early juvenile idiopathic arthritis do better by starting with one treatment approach and adjusting (stepping up or stepping down) based on how their arthritis responds. It may help find the safest, most effective long-term plan for controlling symptoms with fewer side effects.
Hear when a new Polyarticular Juvenile Idiopathic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.